- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Financial Highlights:**
Nath Bio-Genes reported a total revenue of INR 3,129 Mn for 9MFY25, marking an 8.1% increase YoY. Gross profit was INR 1,651 Mn, with a gross margin of 53%, while EBITDA reached INR 511 Mn, reflecting a 6.7% growth YoY with margins at 16%. Net profit rose to INR 394.3 Mn, an 8.1% increase, resulting in a net profit margin of 12.6%.
**Strategic Initiatives and Growth Drivers:**
The company emphasizes a strategic focus on non-crop portfolio (NCP) segments, maintaining 46% of the portfolio's value. Performance in key crops saw significant growth, including a 21.3% increase in maize value and a 16.6% rise in paddy.
**Business Developments:**
Nath Bio-Genes is expanding its international presence, with successful collaboration in the Philippines and ongoing joint ventures in Uzbekistan. This aligns with their goal of enhancing global market reach.
**Market Position and Competitive Advantage:**
With a network of around 20,000 distributors and dealers across 23 states, Nath Bio-Genes is strategically positioned to leverage its superior supply chain and diversified product offerings.
**Investor Implications:**
The positive financial growth and strategic initiatives suggest a favorable outlook for investors. Continued expansion in international markets and strong positioning in high-demand crops highlight potential growth opportunities amidst a competitive landscape.